2-氯甲基-5-(4-甲氧基苯基)-1,3-氧二唑 | 24023-71-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-氯甲基-5-(4-甲氧基苯基)-1,3-氧二唑
• 中文别名: 2-氯甲基-5-(4-甲氧基苯基)-1,2,4-噁二唑
• 英文名称: 2-(chloromethyl)-5-(4-methoxyphenyl)-1,3,4-oxadiazole
• CAS: 24023-71-0
• 化学式: C₁₀H₉ClN₂O₂
• mdl: MFCD01230030
• 分子量: 224.647
• InChiKey: GEHIXSKXGCIKJJ-UHFFFAOYSA-N

物化性质

• 熔点：
  91-95 °C
• 密度：
  1.3919 (rough estimate)
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  48.2
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 储存条件：
  应存放在阴凉干燥处。

SDS

Name:	2-Chloromethyl-5-(4-Methoxyphenyl)-1 2 4-Oxadiazole 98% Material Safety Data Sheet
Synonym:	None Known
CAS:	24023-71-0

Section 1 - Chemical Product MSDS Name:2-Chloromethyl-5-(4-Methoxyphenyl)-1 2 4-Oxadiazole 98% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
24023-71-0	2-Chloromethyl-5-(4-Methoxyphenyl)-1,2	98%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions. Provide ventilation. Vacuum or sweep up material and place into a suitable, dry disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 24023-71-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: light yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 91 - 95 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H9ClN2O2
Molecular Weight: 224.5282

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 24023-71-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Chloromethyl-5-(4-Methoxyphenyl)-1,2,4-Oxadiazole - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 24023-71-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 24023-71-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 24023-71-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯甲基-5-(4-甲氧基苯基)-1,3-氧二唑 在 吡啶 、 氢气 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 乙腈 为溶剂， 反应 48.25h， 生成 N-(3-fluoro-4-((5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methoxy)phenyl)benzenesulfonamide
  参考文献：
  名称：

  Synthesis and in vitro antiproliferative activity of new 1,3,4-oxadiazole derivatives possessing sulfonamide moiety

  摘要：

  Synthesis of a new series of 1,3,4-oxadiazole derivatives possessing sulfonamide moiety is described. Their in vitro antiproliferative activities against NCI-58 human cancer cell lines of nine different cancer types were tested. Compound 1k with p-methoxybenzenesulfonamido moiety showed the highest mean %inhibition value over the 58 cell line panel at 10 mu M concentration. It showed broad-spectrum antiproliferative activity over many cell lines of different cancer types. For instance, compound 1k inhibited the growth of T-47D breast cancer cell line by 90.47% at 10 mu M. And it inhibited growth of SR leukemia, SK-MEL-5 melanoma, and MDA-MB-468 breast cancer cell lines by more than 80% at the same test concentration. Compound 1k showed superior activity than Paditaxel and Gefitinib against the most sensitive cell lines. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.11.011
• 作为产物：
  描述：

  对甲氧基苯甲酰肼 在 三氯氧磷 作用下， 以 乙酸乙酯 为溶剂， 生成 2-氯甲基-5-(4-甲氧基苯基)-1,3-氧二唑
  参考文献：
  名称：

  设计和合成新的诺氟沙星-1,3,4-恶二唑杂种作为对耐甲氧西林的金黄色葡萄球菌（MRSA）的抗菌剂。

  摘要：

  为了寻找新的抗菌药物来控制耐甲氧西林的金黄色葡萄球菌（MRSA），设计并合成了一类新的诺氟沙星-1,3,4-恶二唑杂种。评估了对药物敏感细菌金黄色葡萄球菌和MRSA临床耐药菌株的抗菌活性。化合物5k对金黄色葡萄球菌（MIC：2μg/ mL）和MRSA1-3（MIC：0.25-1μg/ mL）表现出优异的抗菌活性。时间杀灭动力学表明，化合物5k在杀死金黄色葡萄球菌和MRSA方面优于常用抗生素万古霉素。而且，化合物5k可以在短时间内抑制细菌并破坏其膜，并且对NRK-52E细胞显示出非常低的细胞毒性。还讨论了一些有趣的结构-活性关系（SAR）。这些结果表明这些诺氟沙星1,3，

  DOI：

  10.1016/j.ejps.2019.104966

文献信息

• Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety
  作者：Fatma A.F. Ragab、Sahar M. Abou-Seri、Salah A. Abdel-Aziz、Abdallah M. Alfayomy、Mohamed Aboelmagd

  DOI：10.1016/j.ejmech.2017.06.026

  日期：2017.9

  A series of dihydropyrimidine (DHPM) derivatives bearing 1,3,4-oxadiazole moiety was designed and synthesized as monastrol analogues. The new compounds were screened for their cytotoxic activity toward 60 cancer cell lines according to NCI (USA) protocol. Seven compounds were further examined against the most sensitive cell lines, leukemia HL-60(TB) and MOLT-4. The most active compounds were 9m against

  设计并合成了一系列带有1,3,4-恶二唑部分的二氢嘧啶（DHPM）衍生物，作为monastrol类似物。根据NCI（USA）方案，筛选了这些新化合物对60种癌细胞系的细胞毒活性。进一步针对最敏感的细胞系白血病HL-60（TB）和MOLT-4检测了7种化合物。活性最高的化合物对HL-60（TB）的 抗性为9m（IC 50  = 56 nM），对MOLT-4的活性为9n（IC 50 = 80 nM），比蒙那那尔更强（分别为IC 50  = 147和215 nM）。9m处理的HL-60（TB）细胞和9n处理的MOLT-4细胞的细胞周期分析 如膜联蛋白V-FITC染色所显示的，显示出在G2 / M期的细胞周期停滞和促凋亡活性。
• Synthesis and Antimicrobial Evaluation of Aminoguanidine and 3-amino- 1,2,4-triazole Derivatives as Potential Antibacterial Agents
  作者：Tian-Yi Zhang、Chao Li、Ya-Ru Li、Xiao-Zhen Li、Liang-Peng Sun、Chang-Ji Zheng、Hu-Ri Piao

  DOI：10.2174/1570180813666160819151239

  日期：2016.10.31

  A series of aminoguanidine derivatives bearing a 1,3,4-oxadiazole or piperazine moiety has been synthesized and fully characterized together with a series of 3-amino-1,2,4-triazole derivatives, and the resulting compounds were evaluated for their anti-bacterial activity. Most of these compounds showed broad-spectrum antibacterial activities against both Gram-positive and Gram-negative bacteria with

  已合成了一系列带有1,3,4-恶二唑或哌嗪部分的氨基胍衍生物，并与一系列3-氨基-1,2,4-三唑衍生物一起进行了全面表征，并评估了所得化合物的抗-细菌活性。这些化合物大多数对革兰氏阳性和革兰氏阴性细菌均具有广谱抗菌活性，其最低抑菌浓度（MIC）和最低杀菌浓度（MBC）值在1–64μg/ mL范围内，包括耐多药临床分离株和真菌。值得注意的是，化合物19e和19f的抗甲氧西林金黄色葡萄球菌（3167和3506）和喹诺酮抗S的活性高于加替沙星和莫西沙星。金黄色葡萄球菌（3505和3519）的MIC和MBC值在1-2 µg / mL范围内。这两种化合物还显示出显着的抗真菌活性，对白色念珠菌7535的MIC值为1μg/ mL，相当于标准药物氟康唑的MIC值。因此，这些结果表明，不含哌嗪部分的氨基胍衍生物是开发新型抗菌剂的令人感兴趣的支架。
• An Old Story in the Parallel Synthesis World: An Approach to Hydantoin Libraries
  作者：Andrey V. Bogolubsky、Yurii S. Moroz、Olena Savych、Sergey Pipko、Angelika Konovets、Maxim O. Platonov、Oleksandr V. Vasylchenko、Vasyl V. Hurmach、Oleksandr O. Grygorenko

  DOI：10.1021/acscombsci.7b00163

  日期：2018.1.8

  An approach to the parallel synthesis of hydantoin libraries by reaction of in situ generated 2,2,2-trifluoroethylcarbamates and α-amino esters was developed. To demonstrate utility of the method, a library of 1158 hydantoins designed according to the lead-likeness criteria (MW 200–350, cLogP 1–3) was prepared. The success rate of the method was analyzed as a function of physicochemical parameters

  开发了一种通过原位生成的2,2,2-三氟乙基氨基甲酸酯与α-氨基酯反应平行合成乙内酰脲文库的方法。为了证明该方法的实用性，准备了根据铅样标准（MW 200–350，cLogP 1-3）设计的1158个乙内酰脲文库。分析了该方法的成功率与产品理化参数的关系，发现该方法可以被认为是用于铅导向合成的工具。通过合理设计，使用开发的方法进行平行合成，计算机模拟和体外筛选相结合的方法，发现了一种含乙内酰脲的超微摩尔主要分子，可作为Aurora激酶A抑制剂。
• Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them
  申请人：Leivers Martin Robert

  公开号：US20100029655A1

  公开（公告）日：2010-02-04

  Disclosed are processes for the preparation of compounds of formula I and compositions that comprise said compounds of formula I. Also disclosed are processes for the preparation of compounds of formula III and compositions that comprise said compounds of formula III.

  公开了制备公式I化合物的过程以及包含所述公式I化合物的组合物。 还公开了制备公式III化合物的过程以及包含所述公式III化合物的组合物。
• Design and synthesis of pyrimidine-5-carbonitrile hybrids as COX-2 inhibitors: Anti-inflammatory activity, ulcerogenic liability, histopathological and docking studies
  作者：Abdallah M. Alfayomy、Salah A. Abdel-Aziz、Adel A. Marzouk、Montaser Sh. A. Shaykoon、Atsushi Narumi、Hiroyuki Konno、Sahar M. Abou-Seri、Fatma A.F. Ragab

  DOI：10.1016/j.bioorg.2020.104555

  日期：2021.3

  Two new series of 1,3,4-oxadiazole and coumarin derivatives based on pyrimidine-5-carbonitrile scaffold have been synthesized and evaluated for their COX-1/COX-2 inhibitory activity. Compounds 10c, 10e, 10h-j, 14e-f, 14i and 16 were found to be the most potent and selective inhibitors of COX-2 (IC50 0.041-0.081 μM, SI 139.74-321.95). Eight compounds were further investigated for their in vivo anti-inflammatory

  合成了两个新系列的基于 pyrimidine-5-carbonitrile 支架的 1,3,4-恶二唑和香豆素衍生物，并评估了它们的 COX-1/COX-2 抑制活性。发现化合物10c、10e、10h-j、14e-f、14i和16是最有效和选择性的 COX-2 抑制剂（IC 50 0.041-0.081 μM，SI 139.74-321.95）。进一步研究了八种化合物的体内抗炎活性。最活跃的衍生物10c , 10j和14e显示出优于参考药物塞来昔布的体内抗炎活性（水肿抑制百分比 39.3-48.3，1 小时；58.4-60.5，2 小时；70.8-83.2，3 小时；78.9-89.5，4 小时）（水肿抑制百分比 38.0） ，1 小时；48.8、2 小时；58.4、3 小时；65.4、4 小时）。还测试了这些衍生物的致溃疡倾向，化合物10j与塞来昔布相比表现出更好的安全性，而10c和14e表现出轻度损伤。COX-2